Zinc finger protein A20 protects rats against chronic liver allograft dysfunction

doi:10.3748/wjg.v18.i27.3537

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 27

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4062)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-3) series.

Item

Count

PDF

387

HTML

3211

Figures (1-6)

284

Tables (1-3)

180

Sum=4062

Jul 21, 2012 (publication date) through Nov 13, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Jul 21, 2012; 18(27): 3537-3550
Published online Jul 21, 2012. doi: 10.3748/wjg.v18.i27.3537

Table 1 Effect of A20 on the survival of Lewis rats transplanted with Dark Agouti livers

Treatment¹	Survival (d)	mean ± SD
FK506 + PS	52, 57, 60, 72, 78	63.80 ± 10.83
FK506 + rAdEasy A20	117, 121, 123, 128, 136	125.00 ± 7.31^a
FK506 + rAdEasy	44, 50, 57, 58, 67	55.20 ± 8.70

¹Lewis rats transplanted with Dark Agouti livers were given 0.1 mg/kg FK506 for 5 d after transplantation. Lewis rats receiving transplants were given rAdEasy-A20 (1 × 10⁹ pfu/30 g weight) or rAdEasy or physiological saline (PS) once every 10 d from postoperative day (POD) 30 to POD 90.

^aP < 0.01 vs FK506 + PS and FK506 + rAdEasy treatment.

Table 2 Serum total bilirubin and alanine aminotransferase levels after liver transplantation (n = 5)

Group	ALT (IU/L)		TBIL(μmol/L)
	POD 30	POD 60	POD 30	POD 60
FK506 + PS	163.41 ± 35.28	257.35 ± 42.78	85.72 ± 16.47	165.43 ± 24.63
FK506 + A20	66.79 ± 17.56^b	90.28 ± 22.37^b^d	37.61 ± 8.06^b	63.71 ± 11.38^b^d
FK506 + rAdEasy	187.66 ± 43.54	282.75 ± 53.64^d	106.37 ± 21.35	182.93 ± 28.75^d

^bP < 0.01 vs FK506 + physiological saline (PS) or FK506 + rAdEasy;

^dP < 0.01 vs postoperative day (POD) 30. ALT: Alanine aminotransferase; TBIL: Total bilirubin.

Table 3 Tumor growth factor-β1 levels in the conditioned media of cultured hepatic stellate cells (n = 5)

Group	TGF-β1 (pg/mL, mean ± SD)
	POD 30	POD 60
FK506 + PS	1385.80 ± 186.84^b	2368.62 ± 211.58^b^d
FK506 + A20	595.76 ± 85.71	718.28 ± 97.12
FK506 + rAdEasy	1525.32 ± 202.66^b	2475.33 ± 194.93^b^d

^bP < 0.01 vs FK506 + A20;

^dP < 0.01 vs postoperative day (POD) 30. TGF-β1: Tumor growth factor-β1.

Citation: Yang J, Xu MQ, Yan LN, Chen XB, Liu J. Zinc finger protein A20 protects rats against chronic liver allograft dysfunction. World J Gastroenterol 2012; 18(27): 3537-3550
URL: https://www.wjgnet.com/1007-9327/full/v18/i27/3537.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i27.3537